704 related articles for article (PubMed ID: 25880495)
21. EGFR is a Therapeutic Target in Hormone Receptor-Positive Breast Cancer.
Jeong Y; Bae SY; You D; Jung SP; Choi HJ; Kim I; Lee SK; Yu J; Kim SW; Lee JE; Kim S; Nam SJ
Cell Physiol Biochem; 2019; 53(5):805-819. PubMed ID: 31670920
[TBL] [Abstract][Full Text] [Related]
22. Preparation and characterization of Tamoxifen citrate loaded nanoparticles for breast cancer therapy.
Maji R; Dey NS; Satapathy BS; Mukherjee B; Mondal S
Int J Nanomedicine; 2014; 9():3107-18. PubMed ID: 25028549
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and characterization of tumor-targeted copolymer nanocarrier modified by transferrin.
Liu R; Wang Y; Li X; Bao W; Xia G; Chen W; Cheng J; Xu Y; Guo L; Chen B
Drug Des Devel Ther; 2015; 9():2705-19. PubMed ID: 26045659
[TBL] [Abstract][Full Text] [Related]
24. An autocrine VEGF/VEGFR2 and p38 signaling loop confers resistance to 4-hydroxytamoxifen in MCF-7 breast cancer cells.
Aesoy R; Sanchez BC; Norum JH; Lewensohn R; Viktorsson K; Linderholm B
Mol Cancer Res; 2008 Oct; 6(10):1630-8. PubMed ID: 18922978
[TBL] [Abstract][Full Text] [Related]
25. Preparation and in vitro evaluation of meloxicam-loaded PLGA nanoparticles on HT-29 human colon adenocarcinoma cells.
Şengel-Türk CT; Hasçiçek C; Dogan AL; Esendagli G; Guc D; Gönül N
Drug Dev Ind Pharm; 2012 Sep; 38(9):1107-16. PubMed ID: 22348284
[TBL] [Abstract][Full Text] [Related]
26. MiR-214 increases the sensitivity of breast cancer cells to tamoxifen and fulvestrant through inhibition of autophagy.
Yu X; Luo A; Liu Y; Wang S; Li Y; Shi W; Liu Z; Qu X
Mol Cancer; 2015 Dec; 14():208. PubMed ID: 26666173
[TBL] [Abstract][Full Text] [Related]
27. Full activation of estrogen receptor alpha activation function-1 induces proliferation of breast cancer cells.
Fujita T; Kobayashi Y; Wada O; Tateishi Y; Kitada L; Yamamoto Y; Takashima H; Murayama A; Yano T; Baba T; Kato S; Kawabe Y; Yanagisawa J
J Biol Chem; 2003 Jul; 278(29):26704-14. PubMed ID: 12738788
[TBL] [Abstract][Full Text] [Related]
28. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
[TBL] [Abstract][Full Text] [Related]
29. Orlistat and antisense-miRNA-loaded PLGA-PEG nanoparticles for enhanced triple negative breast cancer therapy.
Bhargava-Shah A; Foygel K; Devulapally R; Paulmurugan R
Nanomedicine (Lond); 2016 Feb; 11(3):235-47. PubMed ID: 26787319
[TBL] [Abstract][Full Text] [Related]
30. Pharmacological Inhibition of MCT4 Reduces 4-Hydroxytamoxifen Sensitivity by Increasing HIF-1α Protein Expression in ER-Positive MCF-7 Breast Cancer Cells.
Nadai T; Narumi K; Furugen A; Saito Y; Iseki K; Kobayashi M
Biol Pharm Bull; 2021; 44(9):1247-1253. PubMed ID: 34471053
[TBL] [Abstract][Full Text] [Related]
31. Translocator protein ligand-PLGA conjugated nanoparticles for 5-fluorouracil delivery to glioma cancer cells.
Laquintana V; Denora N; Lopalco A; Lopedota A; Cutrignelli A; Lasorsa FM; Agostino G; Franco M
Mol Pharm; 2014 Mar; 11(3):859-71. PubMed ID: 24410438
[TBL] [Abstract][Full Text] [Related]
32. Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death.
Obrero M; Yu DV; Shapiro DJ
J Biol Chem; 2002 Nov; 277(47):45695-703. PubMed ID: 12244117
[TBL] [Abstract][Full Text] [Related]
33. Folic acid-decorated and PEGylated PLGA nanoparticles for improving the antitumour activity of 5-fluorouracil.
El-Hammadi MM; Delgado ÁV; Melguizo C; Prados JC; Arias JL
Int J Pharm; 2017 Jan; 516(1-2):61-70. PubMed ID: 27825867
[TBL] [Abstract][Full Text] [Related]
34. Enhanced Antitumor Efficacy and Reduced Toxicity of Docetaxel Loaded Estradiol Functionalized Stealth Polymeric Nanoparticles.
Jain S; Spandana G; Agrawal AK; Kushwah V; Thanki K
Mol Pharm; 2015 Nov; 12(11):3871-84. PubMed ID: 26375023
[TBL] [Abstract][Full Text] [Related]
35. Differential recruitment of coregulator proteins steroid receptor coactivator-1 and silencing mediator for retinoid and thyroid receptors to the estrogen receptor-estrogen response element by beta-estradiol and 4-hydroxytamoxifen in human breast cancer.
Fleming FJ; Hill AD; McDermott EW; O'Higgins NJ; Young LS
J Clin Endocrinol Metab; 2004 Jan; 89(1):375-83. PubMed ID: 14715875
[TBL] [Abstract][Full Text] [Related]
36. MicroRNA-574-3p, identified by microRNA library-based functional screening, modulates tamoxifen response in breast cancer.
Ujihira T; Ikeda K; Suzuki T; Yamaga R; Sato W; Horie-Inoue K; Shigekawa T; Osaki A; Saeki T; Okamoto K; Takeda S; Inoue S
Sci Rep; 2015 Jan; 5():7641. PubMed ID: 25560734
[TBL] [Abstract][Full Text] [Related]
37. Effective cellular internalization, cell cycle arrest and improved pharmacokinetics of Tamoxifen by cholesterol based lipopolymeric nanoparticles.
Mazumdar S; Italiya KS; Sharma S; Chitkara D; Mittal A
Int J Pharm; 2018 May; 543(1-2):96-106. PubMed ID: 29578081
[TBL] [Abstract][Full Text] [Related]
38. Exploiting off-target effects of estrogen deprivation to sensitize estrogen receptor negative breast cancer to immune killing.
Wolfson B; Padget MR; Schlom J; Hodge JW
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34244306
[TBL] [Abstract][Full Text] [Related]
39. Nanoencapsulation of pomegranate bioactive compounds for breast cancer chemoprevention.
Shirode AB; Bharali DJ; Nallanthighal S; Coon JK; Mousa SA; Reliene R
Int J Nanomedicine; 2015; 10():475-84. PubMed ID: 25624761
[TBL] [Abstract][Full Text] [Related]
40. A role for macroautophagy in protection against 4-hydroxytamoxifen-induced cell death and the development of antiestrogen resistance.
Samaddar JS; Gaddy VT; Duplantier J; Thandavan SP; Shah M; Smith MJ; Browning D; Rawson J; Smith SB; Barrett JT; Schoenlein PV
Mol Cancer Ther; 2008 Sep; 7(9):2977-87. PubMed ID: 18790778
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
